The company is preparing to provide a clinical testing service that integrates hydrogen and methane biomarkers for digestive health conditions.
The research group believes a computer-sized instrument that uses its fluorescence technology could be deployed in clinical laboratories to test 500 samples in one hour.
The group's printable biosensor plugs into a computer or smartphone and uses receptor ACE2 as well saliva or a nasal swab to detect SARS-CoV-2.
Bulk acoustic wave technology detects changes in resonance frequency in a biosensor and enables a limit of detection near that of molecular tests, the firm said.
GBS said it expects that later this year it will launch a multiplex assay, which it is developing with the Wyss Institute, to detect antibodies against SARS-CoV-2.
The company plans on launching two new iterations of its Pheno platforms this year, and one in late 2023.
The company has invested revenues from its pandemic testing business to buy assets that are growing faster than its base business.
MindX has inked a deal that enables Q2 Solutions to use whole-transcriptome analysis for psychiatric blood tests as part of an early-access program for physicians.
The firm said that recent validation studies have shown that a positive result with its PanCan-d microarray test could accelerate diagnosis for high-risk individuals.
On the back of a recently announced $3 million in funding, the firm has begun marketing its Urodiag kit to urologists throughout Europe.